Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities and Shareholders Equity (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $190.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 6.15% to $190.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $758.0 million through Dec 2025, down 21.09% year-over-year, with the annual reading at $190.3 million for FY2025, 6.15% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $190.3 million at Anika Therapeutics, roughly flat from $189.4 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $363.1 million in Q2 2021, with the low at $187.7 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $290.2 million, with a median of $328.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity increased 0.46% in 2022, then decreased 29.48% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $347.5 million in 2021, then rose by 0.46% to $349.1 million in 2022, then dropped by 22.48% to $270.6 million in 2023, then fell by 25.09% to $202.7 million in 2024, then dropped by 6.15% to $190.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $190.3 million, $189.4 million, and $187.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.